Related Experiment Videos
Melatonin treatment for sleep disorders in children with neurodevelopmental disorders: an observational study
Caroline Ross1, Paul Davies, William Whitehouse
1Department of Neurology, Birmingham Children's Hospital NHS Trust, UK. caroline.ross@uhl-tr.nhs.uk
Insights
Melatonin significantly improved sleep in children with neurological conditions, as documented by parent sleep diaries. The treatment was well-tolerated, with no reported adverse effects in this study.
Area of Science:
- Pediatric Neurology
- Sleep Medicine
- Pharmacology
Background:
- Sleep disturbances are common in children with neurological conditions.
- Assessing sleep improvement in pediatric neurology requires objective measures.
- Melatonin is a potential therapeutic agent for sleep disorders.
Purpose of the Study:
- To quantify melatonin's effect on sleep in children with neurological conditions.
- To evaluate sleep improvement using parent-completed sleep diaries.
- To assess the safety and efficacy of melatonin treatment in an outpatient setting.
Main Methods:
- Prospective study involving 49 pediatric patients (aged 1-13 years) with neurological conditions.
- Parent-completed sleep diaries were used to record sleep patterns before and during melatonin treatment.
- Melatonin dosage was optimized to the maximum required dose for each patient.
Main Results:
- Out of 46 assessed patients, 34 (74%) demonstrated sleep improvement with melatonin.
- The most common diagnosis among participants was epilepsy (n=26).
- No adverse effects were attributed to melatonin treatment.
Conclusions:
- Melatonin is an effective and safe treatment for improving sleep in children with neurological disorders.
- Parent-completed sleep diaries provide a valuable tool for assessing treatment efficacy.
- Further research should explore melatonin's role in specific pediatric neurological populations.
Abstract:
The study aim was to quantify melatonin-associated improvement in sleep by means of a parent-completed sleep diary during routine outpatient activity. An investigation into sleep disturbance was made at neurology outpatient appointments. Those parents who identified a problem were asked to complete a sleep diary, after which treatment was initiated. The first week of the diary was completed before treatment, the second when established on the maximum dose of melatonin required. Forty-nine patients (26 males, 23 females) aged from one to 13 years, were treated between 1997 and 1998: 28 of these returned interpretable diaries. In a further 18 patients, an assessment could be made of the usefulness of the treatment. Patients were fairly typical of those attending a tertiary centre, the most common primary diagnosis being epilepsy (n=26). Only seven patients were visually impaired. Of the 46 patients who were assessed, 34 showed an improvement. No adverse effects were attributed to the treatment.